Epilepsy After Antipsychotic Prescription in Survivors of Traumatic Brain Injury: A Population-Based Cohort Study.

Authors

Augusto Ferraris, Alejandro G Szmulewicz, Neill K J Adhikari, Lisa Burry, Alejandro Hernández, Hannah Wunsch, Damon C Scales, Federico Angriman

Published in

Critical care medicine. Sep 21, 2026. Epub Sep 21, 2026.

Abstract

To evaluate whether the choice of antipsychotic treatment following traumatic brain injury (TBI) hospitalization is associated with the risk of post-traumatic epilepsy in older adults.
Retrospective cohort study.
Population-based cohort in Ontario, Canada (2009-2021).
We included adults 66 years or older without epilepsy who survived a first TBI admission and filled new prescriptions for antipsychotics within 30 days after discharge.
None.
The exposure groups included patients who were prescribed haloperidol or risperidone, compared separately to quetiapine. The primary outcome was a new diagnosis of epilepsy up to 5 years following discharge. We used inverse probability of treatment weighting of cause-specific Cox models to calculate adjusted hazard ratios (aHR) and 95% CIs based on a robust variance estimator. Of 1204 TBI survivors included, 202 (17%) filled prescriptions for haloperidol, 300 (25%) for risperidone, and 702 (58%) for quetiapine; epilepsy was diagnosed in 6%, 13%, and 14% of these groups, respectively. Mortality by 5 years of follow-up was 89% for haloperidol, 66% for risperidone, and 62% for quetiapine. Compared with quetiapine, a new prescription for haloperidol (aHR = 0.73; 95% CI, 0.39-1.34) or risperidone (aHR = 0.94; 95% CI, 0.65-1.36) was not associated with higher epilepsy risk.
We found no clear signal of a differential risk of epilepsy when comparing new prescriptions for haloperidol or risperidone with quetiapine among survivors of TBI. Nonetheless, high mortality limited comparability across groups, CIs were wide, and additional studies should confirm our findings.

PMID:
42765799
Bibliographic data and abstract were imported from PubMed on 21 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.